Experienced professional with a strong background in research and quality control, supported by 6 years of dedicated research and 5 years of industry quality control lab experience. Proficient in working with multiple regulatory bodies, including EPA, APHA, and EMEA, ensuring rigorous adherence to quality standards. Seeking a challenging role in drug formulation and delivery as part of a dynamic team. Proven ability to collaborate with drug formulation experts, scientific thought leaders, and R&D teams to develop innovative drug and excipient-based molecule.
Amitriptyline, 3(10,11-dihydro-5H-dibenzo (a,d) cycloheptene-5-ylidene)-N,N-dimethylpropan-1-amine, newer class of selective serotonin reuptake inhibitors (SSRIs). Sustained release (SR) dosage forms release a drug at a predetermined rate to maintain a constant drug concentration in the systemic circulation for an extended period. AMT was formulated with different compositions of the polymer hydroxypropyl methylcellulose (HPMC) K100M to increase SR delivery of the drug in the GI tract and consequently into systemic circulation. Using a wet granulation method, AMT, and various compositions of HPMC K100M were mixed and compressed into tablets using an automatic rotary tablet press. The release of the drug from the tablets was measured using an in vitro dissolution method (USP). The final formulation released 98.95% of the drug in 45 minutes and 97.40% of the drug in 12 hours.
Research Project:
20-HETE, a signalling molecule produced by CYP4A1 from arachidonic acid. 20-HETE is involved in a variety of physiological and pathological processes, including apoptosis, vascular tone, inflammation, and cell growth. Developing drugs that target 20-HETE signalling as potential treatments for these diseases. Pulmonary endothelial cells anti-apoptotic effects of 20-HETE are mediated through signalling pathways including MAPK and PI3K/Akt, as well as through eNOS uncoupling and NOX/ROS production.